#METABOLOMICS WORKBENCH NReisdorphLab_20170427_151108 DATATRACK_ID:899 STUDY_ID:ST000601 ANALYSIS_ID:AN000920 PROJECT_ID:PR000438 VERSION 1 CREATED_ON May 9, 2017, 1:45 pm #PROJECT PR:PROJECT_TITLE Chronic Obstructive Pulmonary Disease Human Plasma Metabolomics PR:PROJECT_TYPE Untargeted LC-MS Metabolomics PR:PROJECT_SUMMARY COPD is a very heterogeneous disease comprising multiple phenotypes. Plasma from PR:PROJECT_SUMMARY 131 human subjects was collected as part of the NIH-sponsored COPDGene cohort PR:PROJECT_SUMMARY and analyzed using untargeted LC-MS (C18+) and (HILIC+) metabolomics. The goal PR:PROJECT_SUMMARY was to identify perturbed compounds and pathways associated with COPD. PR:INSTITUTE University of Colorado, Denver PR:DEPARTMENT Pharmaceutical Sciences, Anschutz Medical Campus PR:LAST_NAME Nichole PR:FIRST_NAME Reisdorph PR:ADDRESS 12850 East Montview Blvd, Aurora, CO 80045 PR:EMAIL Nichole.Reisdorph@ucdenver.edu PR:PHONE 303-724-9243 PR:FUNDING_SOURCE NIH P20 #STUDY ST:STUDY_TITLE Untargeted LC-MS metabolomics analysis of human COPD plasma, HILIC & C18 ST:STUDY_SUMMARY Identify perturbed metabolites and pathways in human plasma collected from 131 ST:STUDY_SUMMARY COPD subjects. Subjects were either current or former smokers with various COPD ST:STUDY_SUMMARY phenotypes including emphysema, and exacerbations. ST:INSTITUTE University of Colorado Anschutz Medical Campus ST:LAST_NAME Reisdorph ST:FIRST_NAME Nichole ST:ADDRESS 12850 East Montview Blvd, Aurora, CO 80045 ST:EMAIL Nichole.Reisdorph@ucdenver.edu ST:PHONE 303-724-9243 ST:TOTAL_SUBJECTS 131 ST:NUM_MALES 56 ST:NUM_FEMALES 75 #SUBJECT SU:SUBJECT_TYPE Human Plasma SU:SUBJECT_SPECIES Homo sapiens SU:TAXONOMY_ID 9606 SU:AGE_OR_AGE_RANGE 57-70 SU:GENDER Males and Females SU:HUMAN_RACE Non-Hispanic White SU:HUMAN_SMOKING_STATUS Current and Former Smokers #SUBJECT_SAMPLE_FACTORS: SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Additional sample data SUBJECT_SAMPLE_FACTORS - 10062C Smoking Status:- | Gold Stage:3 Age=64.6; Gender=1; BMI=27.71; FEV1/FVC=0.46; FEV1 percent predicted=36.6; BDR=1; % Emphysema=NA; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 10071D Smoking Status:- | Gold Stage:2 Age=66.1; Gender=1; BMI=32.64; FEV1/FVC=0.65; FEV1 percent predicted=54; BDR=-; % Emphysema=4.0476; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 10087S Smoking Status:- | Gold Stage:2 Age=65.5; Gender=2; BMI=26.58; FEV1/FVC=0.49; FEV1 percent predicted=52.7; BDR=1; % Emphysema=21.2527; Exacerbation Frequency=1 SUBJECT_SAMPLE_FACTORS - 10097V Smoking Status:- | Gold Stage:3 Age=75.7; Gender=2; BMI=23.62; FEV1/FVC=0.43; FEV1 percent predicted=31.7; BDR=-; % Emphysema=16.3921; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 10102O Smoking Status:- | Gold Stage:- Age=61.2; Gender=1; BMI=30.82; FEV1/FVC=0.78; FEV1 percent predicted=94; BDR=-; % Emphysema=1.5828; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 10104S Smoking Status:1 | Gold Stage:- Age=50.6; Gender=2; BMI=26.87; FEV1/FVC=0.76; FEV1 percent predicted=95.7; BDR=1; % Emphysema=0.965; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 10136F Smoking Status:- | Gold Stage:- Age=60.6; Gender=2; BMI=24.4; FEV1/FVC=0.71; FEV1 percent predicted=100.9; BDR=-; % Emphysema=1.0879; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 10138J Smoking Status:- | Gold Stage:2 Age=55.7; Gender=2; BMI=17.92; FEV1/FVC=0.69; FEV1 percent predicted=59.7; BDR=NA; % Emphysema=0.3687; Exacerbation Frequency=1 SUBJECT_SAMPLE_FACTORS - 10166O Smoking Status:- | Gold Stage:1 Age=46.2; Gender=1; BMI=26.01; FEV1/FVC=0.66; FEV1 percent predicted=84.2; BDR=1; % Emphysema=2.6603; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 10170F Smoking Status:- | Gold Stage:4 Age=68.4; Gender=1; BMI=22.22; FEV1/FVC=0.32; FEV1 percent predicted=23.7; BDR=1; % Emphysema=15.3613; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 10182M Smoking Status:- | Gold Stage:3 Age=65.3; Gender=1; BMI=37.33; FEV1/FVC=0.46; FEV1 percent predicted=36; BDR=-; % Emphysema=NA; Exacerbation Frequency=1 SUBJECT_SAMPLE_FACTORS - 10245K Smoking Status:- | Gold Stage:2 Age=66.4; Gender=1; BMI=25.22; FEV1/FVC=0.39; FEV1 percent predicted=54.9; BDR=-; % Emphysema=24.264; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 10300S Smoking Status:- | Gold Stage:3 Age=71.3; Gender=2; BMI=29.11; FEV1/FVC=0.42; FEV1 percent predicted=38.8; BDR=-; % Emphysema=11.2753; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 10328O Smoking Status:- | Gold Stage:3 Age=73.8; Gender=1; BMI=26.65; FEV1/FVC=0.55; FEV1 percent predicted=40.2; BDR=-; % Emphysema=17.5086; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 10390T Smoking Status:1 | Gold Stage:4 Age=73.1; Gender=1; BMI=17.32; FEV1/FVC=0.34; FEV1 percent predicted=29.3; BDR=1; % Emphysema=27.0944; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 10455V Smoking Status:- | Gold Stage:4 Age=65.9; Gender=1; BMI=36.55; FEV1/FVC=0.38; FEV1 percent predicted=25.8; BDR=-; % Emphysema=2.1089; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 10458B Smoking Status:- | Gold Stage:3 Age=70.5; Gender=2; BMI=23.23; FEV1/FVC=0.37; FEV1 percent predicted=31.6; BDR=1; % Emphysema=26.8499; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 10465Y Smoking Status:- | Gold Stage:- Age=72.5; Gender=1; BMI=21.41; FEV1/FVC=0.79; FEV1 percent predicted=103.9; BDR=-; % Emphysema=4.178; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 10473X Smoking Status:- | Gold Stage:2 Age=66.3; Gender=1; BMI=30.7; FEV1/FVC=0.61; FEV1 percent predicted=52.1; BDR=-; % Emphysema=2.1597; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 10544U Smoking Status:- | Gold Stage:2 Age=58.8; Gender=1; BMI=28.59; FEV1/FVC=0.41; FEV1 percent predicted=57.7; BDR=NA; % Emphysema=24.6265; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 10636Z Smoking Status:- | Gold Stage:2 Age=56.7; Gender=2; BMI=35.85; FEV1/FVC=0.62; FEV1 percent predicted=65.8; BDR=1; % Emphysema=3.4625; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 10687Q Smoking Status:- | Gold Stage:- Age=71.4; Gender=2; BMI=22.83; FEV1/FVC=0.79; FEV1 percent predicted=98.1; BDR=-; % Emphysema=0.9173; Exacerbation Frequency=5 SUBJECT_SAMPLE_FACTORS - 11070G Smoking Status:- | Gold Stage:3 Age=65.6; Gender=1; BMI=24.28; FEV1/FVC=0.31; FEV1 percent predicted=32.1; BDR=-; % Emphysema=11.6625; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 11218M Smoking Status:- | Gold Stage:4 Age=71.9; Gender=1; BMI=38.56; FEV1/FVC=0.33; FEV1 percent predicted=25; BDR=1; % Emphysema=17.1307; Exacerbation Frequency=5 SUBJECT_SAMPLE_FACTORS - 12593R Smoking Status:- | Gold Stage:2 Age=52; Gender=1; BMI=27.78; FEV1/FVC=0.5; FEV1 percent predicted=74.5; BDR=-; % Emphysema=5.398; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 12771P Smoking Status:1 | Gold Stage:- Age=48.2; Gender=1; BMI=26.17; FEV1/FVC=0.76; FEV1 percent predicted=88.9; BDR=-; % Emphysema=0.7622; Exacerbation Frequency=1 SUBJECT_SAMPLE_FACTORS - 12778D Smoking Status:- | Gold Stage:3 Age=75.2; Gender=1; BMI=26.31; FEV1/FVC=0.39; FEV1 percent predicted=43.9; BDR=-; % Emphysema=NA; Exacerbation Frequency=1 SUBJECT_SAMPLE_FACTORS - 12900A Smoking Status:- | Gold Stage:2 Age=51.7; Gender=2; BMI=32.95; FEV1/FVC=0.59; FEV1 percent predicted=60.9; BDR=-; % Emphysema=5.3201; Exacerbation Frequency=1 SUBJECT_SAMPLE_FACTORS - 12969K Smoking Status:- | Gold Stage:- Age=78.4; Gender=1; BMI=34.52; FEV1/FVC=0.72; FEV1 percent predicted=88.2; BDR=-; % Emphysema=2.2313; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 13012C Smoking Status:- | Gold Stage:4 Age=54.1; Gender=2; BMI=30.72; FEV1/FVC=0.23; FEV1 percent predicted=23.9; BDR=-; % Emphysema=32.1305; Exacerbation Frequency=3 SUBJECT_SAMPLE_FACTORS - 13686D Smoking Status:- | Gold Stage:3 Age=77.6; Gender=1; BMI=20.31; FEV1/FVC=0.35; FEV1 percent predicted=45.8; BDR=1; % Emphysema=25.434; Exacerbation Frequency=1 SUBJECT_SAMPLE_FACTORS - 13885J Smoking Status:- | Gold Stage:4 Age=62; Gender=2; BMI=26.72; FEV1/FVC=0.29; FEV1 percent predicted=22.1; BDR=1; % Emphysema=16.5458; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 13959M Smoking Status:1 | Gold Stage:4 Age=58.7; Gender=1; BMI=25.64; FEV1/FVC=0.32; FEV1 percent predicted=29.2; BDR=1; % Emphysema=8.5183; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 14303S Smoking Status:- | Gold Stage:4 Age=60.4; Gender=1; BMI=23.36; FEV1/FVC=0.35; FEV1 percent predicted=19.7; BDR=1; % Emphysema=25.6906; Exacerbation Frequency=1 SUBJECT_SAMPLE_FACTORS - 18468S Smoking Status:1 | Gold Stage:2 Age=54.2; Gender=1; BMI=29.62; FEV1/FVC=0.65; FEV1 percent predicted=55.6; BDR=-; % Emphysema=5.9311; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 19370G Smoking Status:- | Gold Stage:3 Age=68.3; Gender=2; BMI=29.67; FEV1/FVC=0.44; FEV1 percent predicted=42.3; BDR=-; % Emphysema=18.9562; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 19688L Smoking Status:- | Gold Stage:2 Age=58.4; Gender=1; BMI=44.87; FEV1/FVC=0.49; FEV1 percent predicted=50; BDR=1; % Emphysema=4.2558; Exacerbation Frequency=2 SUBJECT_SAMPLE_FACTORS - 20542W Smoking Status:1 | Gold Stage:2 Age=59.8; Gender=2; BMI=33.73; FEV1/FVC=0.66; FEV1 percent predicted=74.8; BDR=-; % Emphysema=0.2194; Exacerbation Frequency=2 SUBJECT_SAMPLE_FACTORS - 20580E Smoking Status:- | Gold Stage:3 Age=76.4; Gender=2; BMI=31.15; FEV1/FVC=0.33; FEV1 percent predicted=39.9; BDR=-; % Emphysema=17.2392; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 20696X Smoking Status:1 | Gold Stage:2 Age=54.4; Gender=2; BMI=17.37; FEV1/FVC=0.65; FEV1 percent predicted=75.9; BDR=-; % Emphysema=1.7366; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 20738N Smoking Status:- | Gold Stage:3 Age=75.1; Gender=2; BMI=21.42; FEV1/FVC=0.44; FEV1 percent predicted=46; BDR=-; % Emphysema=30.6821; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 20777X Smoking Status:- | Gold Stage:2 Age=71.1; Gender=2; BMI=35.5; FEV1/FVC=0.67; FEV1 percent predicted=74.2; BDR=-; % Emphysema=3.7824; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 20778Z Smoking Status:- | Gold Stage:2 Age=77; Gender=1; BMI=35.32; FEV1/FVC=0.64; FEV1 percent predicted=71.9; BDR=-; % Emphysema=2.7469; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 20815F Smoking Status:- | Gold Stage:4 Age=71.6; Gender=1; BMI=18.66; FEV1/FVC=0.25; FEV1 percent predicted=25.4; BDR=1; % Emphysema=19.7118; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 20900W Smoking Status:- | Gold Stage:2 Age=77; Gender=1; BMI=39.21; FEV1/FVC=0.66; FEV1 percent predicted=74.6; BDR=-; % Emphysema=2.5072; Exacerbation Frequency=1 SUBJECT_SAMPLE_FACTORS - 21305N Smoking Status:1 | Gold Stage:2 Age=52.4; Gender=2; BMI=40.57; FEV1/FVC=0.68; FEV1 percent predicted=58.7; BDR=-; % Emphysema=0.2529; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 21482J Smoking Status:- | Gold Stage:4 Age=66.2; Gender=1; BMI=15.57; FEV1/FVC=0.33; FEV1 percent predicted=28.8; BDR=-; % Emphysema=19.6359; Exacerbation Frequency=2 SUBJECT_SAMPLE_FACTORS - 21489X Smoking Status:- | Gold Stage:2 Age=52; Gender=1; BMI=36.09; FEV1/FVC=0.66; FEV1 percent predicted=66.1; BDR=-; % Emphysema=3.7679; Exacerbation Frequency=4 SUBJECT_SAMPLE_FACTORS - 21513U Smoking Status:- | Gold Stage:3 Age=71; Gender=2; BMI=40.48; FEV1/FVC=0.56; FEV1 percent predicted=47.5; BDR=-; % Emphysema=1.3905; Exacerbation Frequency=1 SUBJECT_SAMPLE_FACTORS - 21556M Smoking Status:- | Gold Stage:3 Age=60.2; Gender=1; BMI=28.18; FEV1/FVC=0.24; FEV1 percent predicted=38.9; BDR=1; % Emphysema=19.2664; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 21609H Smoking Status:1 | Gold Stage:3 Age=68; Gender=1; BMI=24.68; FEV1/FVC=0.46; FEV1 percent predicted=45.8; BDR=-; % Emphysema=16.7414; Exacerbation Frequency=3 SUBJECT_SAMPLE_FACTORS - 21711Y Smoking Status:- | Gold Stage:- Age=65.2; Gender=1; BMI=25.16; FEV1/FVC=0.76; FEV1 percent predicted=113.5; BDR=-; % Emphysema=0.3225; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 21731E Smoking Status:1 | Gold Stage:2 Age=67.7; Gender=2; BMI=23.39; FEV1/FVC=0.68; FEV1 percent predicted=79.6; BDR=-; % Emphysema=0.2267; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 21897M Smoking Status:- | Gold Stage:1 Age=69.8; Gender=1; BMI=25.5; FEV1/FVC=0.54; FEV1 percent predicted=83.9; BDR=1; % Emphysema=20.543; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 21920H Smoking Status:- | Gold Stage:- Age=57.7; Gender=1; BMI=27.02; FEV1/FVC=0.81; FEV1 percent predicted=100.5; BDR=-; % Emphysema=4.9057; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 21929Z Smoking Status:- | Gold Stage:- Age=57.2; Gender=2; BMI=23.31; FEV1/FVC=0.74; FEV1 percent predicted=97; BDR=-; % Emphysema=0.6702; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 21931M Smoking Status:- | Gold Stage:- Age=59.8; Gender=1; BMI=27.96; FEV1/FVC=0.7; FEV1 percent predicted=98; BDR=-; % Emphysema=2.116; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 21961V Smoking Status:- | Gold Stage:- Age=56.2; Gender=2; BMI=24.1; FEV1/FVC=0.77; FEV1 percent predicted=89.2; BDR=-; % Emphysema=0.4553; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 22155Z Smoking Status:1 | Gold Stage:- Age=61.8; Gender=2; BMI=19.69; FEV1/FVC=0.75; FEV1 percent predicted=84.1; BDR=-; % Emphysema=0.5356; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 22225U Smoking Status:- | Gold Stage:- Age=54.4; Gender=2; BMI=21.03; FEV1/FVC=0.79; FEV1 percent predicted=95.1; BDR=-; % Emphysema=0.4149; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 22363G Smoking Status:1 | Gold Stage:- Age=48.7; Gender=1; BMI=33.22; FEV1/FVC=0.77; FEV1 percent predicted=80.6; BDR=-; % Emphysema=0.4676; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 22375N Smoking Status:- | Gold Stage:- Age=64; Gender=2; BMI=32.8; FEV1/FVC=0.83; FEV1 percent predicted=116.6; BDR=-; % Emphysema=1.2075; Exacerbation Frequency=1 SUBJECT_SAMPLE_FACTORS - 22470H Smoking Status:1 | Gold Stage:- Age=45.2; Gender=2; BMI=24.29; FEV1/FVC=0.79; FEV1 percent predicted=91.6; BDR=-; % Emphysema=0.0516; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 22542G Smoking Status:- | Gold Stage:- Age=62.5; Gender=1; BMI=25.81; FEV1/FVC=0.76; FEV1 percent predicted=103.4; BDR=-; % Emphysema=2.3523; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 22544K Smoking Status:- | Gold Stage:1 Age=71.5; Gender=2; BMI=24.14; FEV1/FVC=0.66; FEV1 percent predicted=83.7; BDR=1; % Emphysema=4.9202; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 22545M Smoking Status:- | Gold Stage:- Age=52.9; Gender=2; BMI=29.48; FEV1/FVC=0.77; FEV1 percent predicted=86.6; BDR=-; % Emphysema=0.9056; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 22569A Smoking Status:- | Gold Stage:- Age=69.8; Gender=1; BMI=26.8; FEV1/FVC=0.85; FEV1 percent predicted=107.8; BDR=-; % Emphysema=0.5447; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 22602Y Smoking Status:1 | Gold Stage:- Age=52.5; Gender=2; BMI=23.36; FEV1/FVC=0.71; FEV1 percent predicted=88.3; BDR=-; % Emphysema=0.469; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 22623G Smoking Status:- | Gold Stage:2 Age=73.4; Gender=1; BMI=31.32; FEV1/FVC=0.6; FEV1 percent predicted=65.6; BDR=1; % Emphysema=13.0636; Exacerbation Frequency=2 SUBJECT_SAMPLE_FACTORS - 22660M Smoking Status:- | Gold Stage:- Age=72.6; Gender=2; BMI=23.81; FEV1/FVC=0.76; FEV1 percent predicted=102.1; BDR=-; % Emphysema=3.4596; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 22691X Smoking Status:1 | Gold Stage:2 Age=58.2; Gender=2; BMI=29.46; FEV1/FVC=0.62; FEV1 percent predicted=75.4; BDR=1; % Emphysema=1.2098; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 22692Z Smoking Status:- | Gold Stage:- Age=48.6; Gender=2; BMI=36.83; FEV1/FVC=0.82; FEV1 percent predicted=104.7; BDR=-; % Emphysema=0.9297; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 22721G Smoking Status:- | Gold Stage:4 Age=57.3; Gender=2; BMI=21.68; FEV1/FVC=0.24; FEV1 percent predicted=18; BDR=1; % Emphysema=23.0203; Exacerbation Frequency=1 SUBJECT_SAMPLE_FACTORS - 22723K Smoking Status:- | Gold Stage:1 Age=57.6; Gender=1; BMI=27.32; FEV1/FVC=0.59; FEV1 percent predicted=84.5; BDR=-; % Emphysema=1.1811; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 22752R Smoking Status:- | Gold Stage:2 Age=75.4; Gender=2; BMI=22.14; FEV1/FVC=0.45; FEV1 percent predicted=62; BDR=-; % Emphysema=21.0042; Exacerbation Frequency=1 SUBJECT_SAMPLE_FACTORS - 22753T Smoking Status:- | Gold Stage:- Age=68.9; Gender=2; BMI=32.07; FEV1/FVC=0.77; FEV1 percent predicted=81.5; BDR=-; % Emphysema=1.2664; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 22754V Smoking Status:- | Gold Stage:2 Age=69.1; Gender=1; BMI=27.79; FEV1/FVC=0.68; FEV1 percent predicted=79.4; BDR=-; % Emphysema=2.1492; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 22756Z Smoking Status:- | Gold Stage:1 Age=56.2; Gender=2; BMI=19.47; FEV1/FVC=0.65; FEV1 percent predicted=82; BDR=-; % Emphysema=NA; Exacerbation Frequency=3 SUBJECT_SAMPLE_FACTORS - 22951X Smoking Status:1 | Gold Stage:- Age=51.4; Gender=2; BMI=35.02; FEV1/FVC=0.81; FEV1 percent predicted=89.4; BDR=-; % Emphysema=0.0886; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 22986Q Smoking Status:1 | Gold Stage:2 Age=49.4; Gender=2; BMI=19.98; FEV1/FVC=0.58; FEV1 percent predicted=69.4; BDR=1; % Emphysema=5.0953; Exacerbation Frequency=1 SUBJECT_SAMPLE_FACTORS - 23089R Smoking Status:- | Gold Stage:4 Age=65.4; Gender=2; BMI=33.46; FEV1/FVC=0.34; FEV1 percent predicted=8.9; BDR=-; % Emphysema=NA; Exacerbation Frequency=2 SUBJECT_SAMPLE_FACTORS - 23090C Smoking Status:- | Gold Stage:1 Age=67.3; Gender=1; BMI=25.31; FEV1/FVC=0.67; FEV1 percent predicted=82.9; BDR=-; % Emphysema=2.9371; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 23091E Smoking Status:- | Gold Stage:- Age=66.4; Gender=2; BMI=30.03; FEV1/FVC=0.71; FEV1 percent predicted=91.5; BDR=-; % Emphysema=7.8524; Exacerbation Frequency=1 SUBJECT_SAMPLE_FACTORS - 23124T Smoking Status:1 | Gold Stage:2 Age=62.4; Gender=2; BMI=24.53; FEV1/FVC=0.43; FEV1 percent predicted=58; BDR=1; % Emphysema=14.8882; Exacerbation Frequency=2 SUBJECT_SAMPLE_FACTORS - 23294S Smoking Status:- | Gold Stage:- Age=77.1; Gender=1; BMI=23.86; FEV1/FVC=0.77; FEV1 percent predicted=112.8; BDR=-; % Emphysema=1.5044; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 23575A Smoking Status:- | Gold Stage:- Age=61.4; Gender=1; BMI=24.33; FEV1/FVC=0.77; FEV1 percent predicted=134.9; BDR=-; % Emphysema=2.6127; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 23611E Smoking Status:1 | Gold Stage:- Age=60.8; Gender=1; BMI=25.31; FEV1/FVC=0.7; FEV1 percent predicted=84.7; BDR=-; % Emphysema=0.4431; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 23744X Smoking Status:1 | Gold Stage:- Age=47; Gender=1; BMI=25.28; FEV1/FVC=0.8; FEV1 percent predicted=127.3; BDR=-; % Emphysema=1.1681; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 23851Y Smoking Status:- | Gold Stage:3 Age=73.5; Gender=2; BMI=26.5; FEV1/FVC=0.43; FEV1 percent predicted=41.9; BDR=-; % Emphysema=20.8766; Exacerbation Frequency=1 SUBJECT_SAMPLE_FACTORS - 24063E Smoking Status:- | Gold Stage:2 Age=69.9; Gender=2; BMI=30.67; FEV1/FVC=0.43; FEV1 percent predicted=66.3; BDR=1; % Emphysema=NA; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 24158P Smoking Status:- | Gold Stage:3 Age=60.7; Gender=2; BMI=19.18; FEV1/FVC=0.38; FEV1 percent predicted=43.4; BDR=-; % Emphysema=38.2897; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 24211T Smoking Status:1 | Gold Stage:2 Age=56.4; Gender=1; BMI=32.48; FEV1/FVC=0.6; FEV1 percent predicted=59.7; BDR=-; % Emphysema=0.5221; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 24213X Smoking Status:1 | Gold Stage:3 Age=56; Gender=1; BMI=19.49; FEV1/FVC=0.43; FEV1 percent predicted=43.3; BDR=-; % Emphysema=47.331; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 24309K Smoking Status:- | Gold Stage:3 Age=63.6; Gender=1; BMI=21.14; FEV1/FVC=0.42; FEV1 percent predicted=31.6; BDR=1; % Emphysema=31.8105; Exacerbation Frequency=1 SUBJECT_SAMPLE_FACTORS - 24344M Smoking Status:- | Gold Stage:- Age=68.4; Gender=2; BMI=21.87; FEV1/FVC=0.79; FEV1 percent predicted=115.1; BDR=-; % Emphysema=1.8584; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 24382U Smoking Status:- | Gold Stage:- Age=79.5; Gender=2; BMI=21.93; FEV1/FVC=0.8; FEV1 percent predicted=123.1; BDR=-; % Emphysema=0.4117; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 24394B Smoking Status:- | Gold Stage:- Age=53.8; Gender=2; BMI=26.06; FEV1/FVC=0.76; FEV1 percent predicted=89.6; BDR=-; % Emphysema=0.4016; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 24429U Smoking Status:- | Gold Stage:2 Age=63.9; Gender=2; BMI=26.73; FEV1/FVC=0.62; FEV1 percent predicted=64.4; BDR=-; % Emphysema=10.7203; Exacerbation Frequency=2 SUBJECT_SAMPLE_FACTORS - 24438V Smoking Status:- | Gold Stage:1 Age=74.7; Gender=1; BMI=30.01; FEV1/FVC=0.65; FEV1 percent predicted=115.2; BDR=-; % Emphysema=19.4956; Exacerbation Frequency=1 SUBJECT_SAMPLE_FACTORS - 24449A Smoking Status:- | Gold Stage:1 Age=61.9; Gender=1; BMI=25.32; FEV1/FVC=0.69; FEV1 percent predicted=80.1; BDR=-; % Emphysema=10.0245; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 24450L Smoking Status:- | Gold Stage:3 Age=69.8; Gender=1; BMI=31.58; FEV1/FVC=0.46; FEV1 percent predicted=42.1; BDR=-; % Emphysema=16.4386; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 24456X Smoking Status:- | Gold Stage:2 Age=73.6; Gender=1; BMI=26.87; FEV1/FVC=0.59; FEV1 percent predicted=63.5; BDR=-; % Emphysema=14.0428; Exacerbation Frequency=3 SUBJECT_SAMPLE_FACTORS - 24513J Smoking Status:1 | Gold Stage:2 Age=58.4; Gender=2; BMI=32.09; FEV1/FVC=0.67; FEV1 percent predicted=63.4; BDR=1; % Emphysema=4.8711; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 24514L Smoking Status:1 | Gold Stage:- Age=66.1; Gender=1; BMI=40.76; FEV1/FVC=0.81; FEV1 percent predicted=81.4; BDR=1; % Emphysema=0.7263; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 24580Y Smoking Status:- | Gold Stage:- Age=55.9; Gender=1; BMI=33.28; FEV1/FVC=0.82; FEV1 percent predicted=97.6; BDR=-; % Emphysema=1.425; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 24593H Smoking Status:- | Gold Stage:3 Age=61.4; Gender=1; BMI=25.03; FEV1/FVC=0.37; FEV1 percent predicted=32.8; BDR=1; % Emphysema=28.2172; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 24639F Smoking Status:- | Gold Stage:4 Age=67.8; Gender=1; BMI=22.39; FEV1/FVC=0.24; FEV1 percent predicted=14.3; BDR=1; % Emphysema=34.1094; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 24653Z Smoking Status:1 | Gold Stage:- Age=61.3; Gender=1; BMI=32.52; FEV1/FVC=0.71; FEV1 percent predicted=99.8; BDR=-; % Emphysema=0.7106; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 24670Z Smoking Status:1 | Gold Stage:3 Age=59.9; Gender=1; BMI=32.12; FEV1/FVC=0.46; FEV1 percent predicted=44.8; BDR=1; % Emphysema=NA; Exacerbation Frequency=1 SUBJECT_SAMPLE_FACTORS - 24673F Smoking Status:- | Gold Stage:2 Age=76; Gender=2; BMI=30.96; FEV1/FVC=0.56; FEV1 percent predicted=60.9; BDR=-; % Emphysema=1.8405; Exacerbation Frequency=2 SUBJECT_SAMPLE_FACTORS - 24678P Smoking Status:- | Gold Stage:4 Age=55.4; Gender=2; BMI=25.01; FEV1/FVC=0.36; FEV1 percent predicted=27.4; BDR=-; % Emphysema=NA; Exacerbation Frequency=3 SUBJECT_SAMPLE_FACTORS - 24706U Smoking Status:1 | Gold Stage:3 Age=67.4; Gender=2; BMI=43.32; FEV1/FVC=0.61; FEV1 percent predicted=40.4; BDR=-; % Emphysema=0.9713; Exacerbation Frequency=1 SUBJECT_SAMPLE_FACTORS - 24716X Smoking Status:- | Gold Stage:- Age=57.2; Gender=1; BMI=33.46; FEV1/FVC=0.83; FEV1 percent predicted=104; BDR=-; % Emphysema=2.2816; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 24718B Smoking Status:1 | Gold Stage:- Age=45.7; Gender=2; BMI=29.02; FEV1/FVC=0.81; FEV1 percent predicted=80.8; BDR=1; % Emphysema=0.8095; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 24739J Smoking Status:- | Gold Stage:1 Age=52.8; Gender=2; BMI=36.8; FEV1/FVC=0.68; FEV1 percent predicted=92.4; BDR=1; % Emphysema=3.4395; Exacerbation Frequency=3 SUBJECT_SAMPLE_FACTORS - 24745E Smoking Status:- | Gold Stage:4 Age=71.8; Gender=2; BMI=19.9; FEV1/FVC=0.28; FEV1 percent predicted=21.6; BDR=1; % Emphysema=27.0988; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 24757L Smoking Status:- | Gold Stage:3 Age=69; Gender=1; BMI=44.66; FEV1/FVC=0.51; FEV1 percent predicted=36.9; BDR=-; % Emphysema=12.4754; Exacerbation Frequency=1 SUBJECT_SAMPLE_FACTORS - 24762E Smoking Status:1 | Gold Stage:2 Age=53.7; Gender=1; BMI=26.68; FEV1/FVC=0.58; FEV1 percent predicted=73.2; BDR=1; % Emphysema=3.7391; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 24825C Smoking Status:- | Gold Stage:2 Age=67.6; Gender=2; BMI=33.26; FEV1/FVC=0.56; FEV1 percent predicted=52; BDR=-; % Emphysema=8.1662; Exacerbation Frequency=1 SUBJECT_SAMPLE_FACTORS - 24826E Smoking Status:- | Gold Stage:- Age=68.9; Gender=1; BMI=28.99; FEV1/FVC=0.76; FEV1 percent predicted=118.6; BDR=-; % Emphysema=1.401; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 24902U Smoking Status:1 | Gold Stage:2 Age=52.8; Gender=2; BMI=27.33; FEV1/FVC=0.61; FEV1 percent predicted=61.1; BDR=-; % Emphysema=0.1815; Exacerbation Frequency=1 SUBJECT_SAMPLE_FACTORS - 24918J Smoking Status:- | Gold Stage:3 Age=62.1; Gender=1; BMI=30.34; FEV1/FVC=0.45; FEV1 percent predicted=40.5; BDR=-; % Emphysema=24.4507; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 24927K Smoking Status:- | Gold Stage:3 Age=62.9; Gender=1; BMI=28.93; FEV1/FVC=0.46; FEV1 percent predicted=44.6; BDR=1; % Emphysema=12.3802; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 24931B Smoking Status:- | Gold Stage:1 Age=79.5; Gender=1; BMI=25.89; FEV1/FVC=0.56; FEV1 percent predicted=84; BDR=-; % Emphysema=17.002; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 25020R Smoking Status:- | Gold Stage:4 Age=61.4; Gender=1; BMI=25.94; FEV1/FVC=0.44; FEV1 percent predicted=15.5; BDR=-; % Emphysema=28.7679; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 25023X Smoking Status:- | Gold Stage:2 Age=78.4; Gender=1; BMI=27.5; FEV1/FVC=0.58; FEV1 percent predicted=59.2; BDR=1; % Emphysema=4.9119; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 25036G Smoking Status:- | Gold Stage:- Age=65.5; Gender=1; BMI=23.68; FEV1/FVC=0.75; FEV1 percent predicted=106.7; BDR=-; % Emphysema=0.4214; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 25214E Smoking Status:- | Gold Stage:- Age=73.3; Gender=1; BMI=27.74; FEV1/FVC=0.73; FEV1 percent predicted=84.5; BDR=-; % Emphysema=0.2548; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 25229R Smoking Status:- | Gold Stage:- Age=59.9; Gender=1; BMI=32.09; FEV1/FVC=0.73; FEV1 percent predicted=80.2; BDR=1; % Emphysema=4.4928; Exacerbation Frequency=1 SUBJECT_SAMPLE_FACTORS - 25237Q Smoking Status:- | Gold Stage:3 Age=67.9; Gender=1; BMI=27.29; FEV1/FVC=0.52; FEV1 percent predicted=45.4; BDR=-; % Emphysema=1.5127; Exacerbation Frequency=- SUBJECT_SAMPLE_FACTORS - 25366B Smoking Status:- | Gold Stage:3 Age=59.6; Gender=1; BMI=27.19; FEV1/FVC=0.42; FEV1 percent predicted=35.6; BDR=1; % Emphysema=20.6796; Exacerbation Frequency=- #COLLECTION CO:COLLECTION_SUMMARY All subjects were from the COPDGene cohort1, an NIH-sponsored multi-centered CO:COLLECTION_SUMMARY study of the genetic epidemiology of COPD. Subjects had fresh frozen plasma CO:COLLECTION_SUMMARY collected using a p100 tube (BD) at one of the COPDGene sites (National Jewish CO:COLLECTION_SUMMARY Health). Additional information on the COPDGene study and the collection of CO:COLLECTION_SUMMARY clinical data has been previously described1.” 1 Regan EA, Hokanson JE, Murphy CO:COLLECTION_SUMMARY JR, Make B, Lynch DA, Beaty TH et al. Genetic epidemiology of COPD (COPDGene) CO:COLLECTION_SUMMARY study design. COPD. 2010;7(1):32-43. doi:10.3109/15412550903499522. CO:SAMPLE_TYPE Plasma CO:BLOOD_SERUM_OR_PLASMA Plasma #TREATMENT TR:TREATMENT_SUMMARY n/a #SAMPLEPREP SP:SAMPLEPREP_SUMMARY 100µL of plasma was prepared using methanol to extract precipitate the proteins SP:SAMPLEPREP_SUMMARY into a pellet. A liquid-liquid extraction with water and methyl-tert butyl ether SP:SAMPLEPREP_SUMMARY (MTBE) was used to partition the supernatant into an aqueous layer and an SP:SAMPLEPREP_SUMMARY organic layer (lipids). The aqueous layer was dried down in a SpeedVac at 45°C, SP:SAMPLEPREP_SUMMARY then reconstituted in 100µL of 95:5 water:acetonitrile. The lipid fraction was SP:SAMPLEPREP_SUMMARY dried down in a SpeedVac at 45°C, then reconstituted in 200µL of 100% SP:SAMPLEPREP_SUMMARY methanol. #CHROMATOGRAPHY CH:CHROMATOGRAPHY_SUMMARY Lipid Fraction (C18) CH:CHROMATOGRAPHY_TYPE Reversed phase CH:INSTRUMENT_NAME Agilent 6210 CH:COLUMN_NAME Agilent Zorbax RRHD SB-C18 (100 x 2.1mm, 1.8um) CH:FLOW_GRADIENT 0-0.5 minutes 30-70% B, 0.5-7.42 minutes 70-100% B, 7.42-9.9 minutes 100% B, CH:FLOW_GRADIENT 9.9-10.0 minutes 100-30% B, followed by column re-equilibration CH:FLOW_RATE 0.7 mL/min CH:COLUMN_TEMPERATURE 60°C CH:SOLVENT_A water with 0.1% formic acid CH:SOLVENT_B 60:36:4 isopropyl alcohol:acetonitrile:water with 0.1% formic acid CH:INJECTION_TEMPERATURE 4°C CH:SAMPLE_INJECTION 4µL CH:CAPILLARY_VOLTAGE 4000V CH:RANDOMIZATION_ORDER Excel rand() function #ANALYSIS AN:ANALYSIS_TYPE MS #MS MS:MS_COMMENTS - MS:INSTRUMENT_NAME Agilent MS:INSTRUMENT_TYPE TOF MS:MS_TYPE ESI MS:ION_MODE POSITIVE MS:FRAGMENT_VOLTAGE 120V MS:SCANNING_RANGE 60-1600m/z MS:SKIMMER_VOLTAGE 60V MS:MS_RESULTS_FILE ST000601_AN000920_Results.txt UNITS:Count #END